Disparities in use of immunotherapy for stage III and IV melanoma patients.

e19087Background: Approval of immune checkpoint inhibitors (ICIs), ipilimumab (ipi), nivolumab and pembrolizumab has significantly changed the outcome for patients with stage III and IV melanoma. A...